FOR IMMEDIATE RELEASE
May 25, 2021 Ann Arbor, MI
Genomenon Welcomes New Director of Customer Success
Dr. Brittnee Jones Joins Leadership Team to Help Clients Maximize the Value of the Mastermind Genomic Search Engine
Genomenon® a leading AI-driven genomics company, recently appointed Dr. Brittnee Jones to their leadership team as the Director of Customer Success. In this role, Brittnee will lead the company’s customer success strategy for Genomenon’s genetic testing lab and pharmaceutical customer base.
“Having spent most of my career facilitating successful genomic intelligence integrations, I fully appreciate the need for comprehensive and efficient tools that support not only life-saving missions, but also the customer journey,” said Jones. “By leveraging the power of genomic language processing and artificial intelligence, Genomenon makes the vast scientific literature accessible in seconds.”
“I cannot be more excited to assist our clients in maximizing the value of Mastermind to benefit their clinical patients and expedite research findings so that the power of precision medicine may be realized.”
Brittnee was most recently the Director of Customer Success at Fabric Genomics, a clinical decision support genomics company with customers across a broad base of clinical labs and hospital systems. Armed with prior experiences at Caribou Biosciences and Fluidigm Corporation, as well as a Ph.D. in chemistry and chemical biology from the University of California, San Francisco, Brittnee has established herself as a data-driven customer success leader in the clinical genomics space.
“We’re excited to have Brittnee join Genomenon as our Director of Customer Success,” said Mike Klein, Chief Executive Officer of Genomenon. “Her extensive background in delivering superior customer experiences within the genomics industry puts her in a unique position to help our customers accelerate their variant interpretation and increase the diagnostic yield of their genetic testing.”
Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.
Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.